Go To Global Site
Welcome to UCB in the United States

Oct

10

UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases

• Will enhance UCB’s leadership potential in myasthenia gravis by adding zilucoplan, a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside to UCB’s rozanolixizumab, an FcRn targeting antibody also in phase 3

Oct

09

It’s Time to Come Together to Deliver More for Patients

At UCB, we keep patients at the center of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. Read more from UCB's CEO and Chairman of the Executive Committee, Jean-Christophe Tellier, about why it's time to come together across all healthcare stakeholders to deliver more for patients.

Oct

03

UCB PharmD Fellows Have a Big Impact on Patients

UCB Global Regulatory Affairs Fellows (L to R): Howraa Alasker, PharmD and Tanya Chaudhri, PharmD, RPh

The 2020-2022 UCB Global Regulatory Affairs (GRA) PharmD Fellowship Program, a collaboration with the Industry Pharmacists Organization (IPhO), is a 2-year rotational program located at UCB’s Atlanta campus aimed at growing top regulatory talent for the future. Established in 2017, the Fellowship Program is designed to provide PharmD graduates with the opportunity to learn and experience all aspects of regulatory affairs under the mentorship of experienced preceptors. Applications are being accepted now until November 1, 2019. Learn more about the fellowship from current fellow, Tanya Chaudhri, PharmD, RPh.

Oct

02

Putting My Passion into Action: Discovering and Advancing Immunology Treatments

As a clinician and researcher, Dr. Victor Sloan is passionate about caring for people living with rheumatic diseases. Read about how he's putting his passion into action by helping to discover and deliver innovative therapies for patients living with non-radiographic axial spondyloarthritis (nr-axSpA).

Sep

27

Patients at the Heart Now and in the Future

Over the last few weeks, we’ve showcased what drives UCB employees to put patients at the heart of everything they do. We believe our future at UCB has never been brighter thanks to the passionate team of UCB employees who dedicate themselves to delivering what patients value each day.

Sep

24

Disease Spotlight: Immune Thrombocytopenia (ITP)

At UCB, we’re focused on helping patients live their best lives. We aim to connect targeted patient populations to cutting-edge science and, in doing so, deliver improved, differentiated experiences to people with the highest unmet needs. September is Immune Thrombocytopenia (ITP) Awareness month, so we’re shining a spotlight on ITP, a rare disease previously known as idiopathic thrombocytopenic purpura.

Sep

19

Unlocking What’s Possible for Patients Through Tech

UCB is committed to discovering and developing new solutions that transform the lives of people living with severe diseases. For Sr. IT Project Lead, Stayce Murray, technology is a key part of this equation to unlock what’s possible. Read more from Stayce about why she puts patients at the heart of everything she does.

Sep

12

UCB and University of Washington Collaborate on Engaging Community Pharmacists to Improve Care for People Living with Epilepsy

UCB is collaborating with the University of Washington to improve care delivery for people living with epilepsy by engaging community pharmacists.

Sep

11

My North Star

At UCB, we're focused on helping patients living with severe diseases that have significant unmet needs. For Dr. Mohamed Yassine, Head of U.S. Medical Affairs, his desire as a doctor shifted from treating individual patients to discovering and developing options that would lead to better outcomes for hundreds of thousands of patients. Read more from Dr. Yassine about why patients are at the heart of everything he does.

Sep

04

Championing Change as a Patient for a Better Tomorrow

At UCB our colleagues come to work laser focused on developing better treatments for patients living with severe diseases. Christof Jensen, Vice President and Head of the Raleigh Site, strives for small successes in this journey and takes opportunities to share insights to hopefully create a better life for others. Read more from Christof about why he puts patients at the heart of everything he does.